The U.S. Food and Drug Administration qualified an AI tool for use in liver disease drug development, Reuters reported on December 8th. The qualification allows the tool to help measure disease progression in clinical trials, giving drug developers a sanctioned way to use automated image analysis when testing treatments. The decision does not approve a medicine or hand clinical judgment to software. It gives a particular instrument a place inside the regulatory grammar of evidence, where a measurement can affect which trials move faster and which patients become legible to a sponsor.

The important shift is bureaucratic and bodily at once. A diseased organ enters the trial as a scan, the scan becomes data, and the data receives a federal permission to count. Medicine has always depended on instruments that translate pain, tissue, pressure, chemistry, and risk into records a committee can read. AI now joins that line of authorized translation. The quieter possibility is that a model becomes part of the gate through which bodies must pass before a treatment is judged promising. The liver remains in the patient. The accepted measurement begins elsewhere, inside a file.